A Phase Ib Dose-escalation Trial of the AKT Inhibitor MK2206 in Combination With Weekly Paclitaxel With or Without Trastuzumab
Phase of Trial: Phase I
Latest Information Update: 01 Feb 2016
At a glance
- Drugs MK 2206 (Primary) ; Paclitaxel; Trastuzumab
- Indications Solid tumours
- Focus Adverse reactions
- 16 Apr 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 18 Nov 2013 Planned end date changed from 1 Dec 2013 to 1 Nov 2013 as reported by ClinicalTrials.gov.
- 18 Nov 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.